UNSPSC 51144010: Fenfluramine

This classification denotes an anorexiant with the molecular formula C12H16F3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2DS058H2CF, chemically known as phenethylamine, n-ethyl-alpha-methyl-m-(trifluoromethyl)-, (s)- but more generally known as fenfluramine, which bears US NIH Compound Identifier 3337. European Medicines Agency schedules Fenfluramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07561MIG. The term FENFLURAMINE is an International Non-Proprietary Name.

UNSPSC 51144010 Fenfluramine is a Commodity code, though the recent state and local opportunities tagged under it show little activity directly aligned with fenfluramine procurement itself. The three most recent solicitations—a Seminole County naloxone and drug deactivation systems bid, a Texas HHS Commission Request for Information on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—indicate the code is being applied broadly to pharmaceutical and health-system procurement rather than to fenfluramine as a discrete product line. State and local governments issuing under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing consortiums seeking to procure pharmaceuticals, naloxone, drug deactivation systems, and generic medication inventories to support community health, pharmacy benefit, and emergency response programs.

Recent activity appears concentrated in Florida, Texas, and Minnesota. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive sealed bid with quarterly deliveries to the County Community Health Building. The Texas HHS Commission (RFI HHS0017013, due April 3, 2026) issued an exploratory Request for Information to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional PBM and wholesaler channels. The Minnesota Department of Administration's MMCAP (S1070000015802, due March 26, 2026) issued a multi-award RFP for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with contracts effective July 1, 2026. Bidders on the MMCAP RFP faced evaluation weighted 75 percent on price competitiveness, with 10 percent on fixed pricing, 5 percent each on administrative compliance, EDI capability, and administrative-fee agreement. The code shows limited direct fenfluramine demand signal in recent state and local procurement.